Ellisor Transitions to Executive Chairman of Vision Source as Greenwood Becomes President and CEO


Jim Greenwood Glenn D. Ellisor, OD

KINGWOOD, Texas— Vision Source’s founder, Glenn D. Ellisor, OD, will transition from chairman and chief executive officer to the newly created position of executive chairman of the corporation effective immediately. Jim Greenwood will assume the role of president and chief executive officer. Greenwood originally joined the company in January as president and chief operating officer.

Ellisor will continue to lead the company’s board of directors and will remain actively involved in the company’s strategy development, including being the full-time clinical lead of the company and setting the strategic direction of the optometric alliance. Working closely with Ellisor, Greenwood will lead the senior team and will be responsible for the execution of major strategic plans, investments and initiatives.

“With the implementation of the Affordable Care Act, the formation of ACOs, physician consolidation, reimbursement pressures and new technologies, it is clear that the industry is facing more, complex change than ever before,” said Ellisor. “My full-time focus will now be how we best serve independent ODs and our members in this rapidly evolving new environment. This is the appropriate time to transition the chief executive responsibilities to Jim.”

Greenwood brings more than 20 years of health care experience and a proven track record of accomplishment at Concentra, a $1 billion physician practice management company, where Greenwood worked in close partnership with clinical leaders during a time of rapid transformational change. Greenwood also serves on the board of directors for several health care organizations and a health care administration program’s advisory council.

Since founding Vision Source in 1991, Ellisor has served as its top executive in various roles including president, chief executive officer and chairman of the board. Since June 1991, he has owned and co-owned several Vision Source practices and currently owns a multi-doctor practice here.

WellPoint Names Advisory Board

INDIANAPOLIS, Ind.— WellPoint, Inc. (NYSE:WLP) has announced the names of the members of its new WellPoint Vision Advisory Board created to help facilitate dialogue with its network of providers. In addition, on July 25, 2013, the managed care company launched a program to include 1-800 CONTACTS as an in-network provider of contact lenses on its vision plans. These initiatives are intended to enhance WellPoint’s vision care offerings by “improving the provider/patient relationship,” Spahr told VM.

The WellPoint Advisory Board members are:
  • Harry Boparai, OD, medical director at New York Vision Group, chief of eyecare at Wyckoff Heights Medical Center and Buena Vida Continuing Care and Rehabilitation Center
  • Heath Gilbert, OD, past president of the Ohio Optometric Association and private practice at Dayton Optometric Center
  • Douglas Kiefer, OD, LensCrafters in Colorado
  • Karin E. Meng, MS, OD, chair, Healthcare Delivery Systems Committee for the California Optometric Association and private practice
  • Steven Richlin, OD, optometry clinic chief, Cedars-Sinai Medical Center, Los Angeles, and private practice
  • Robert E. Smith, OD, staff optometrist,
  • Eye Associates and private practice

James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals

 James Mazzo

CUMBERLAND, R.I.— Neurotech Pharmaceuticals, a biotechnology company developing sight-saving therapies for chronic retinal disease, announced that James Mazzo was appointed the company’s executive chairman. Mazzo, a long time leader in the ophthalmic industry, is the former CEO of Abbott Medical Optics (AMO), is an operating partner at Versant Ventures and was recently named chairman and CEO of AcuFocus, a Versant portfolio company.

As executive chairman, Neurotech said, Mazzo will engage with the Neurotech team to advance the company’s novel technology platform through the clinical development stage toward market availability.

Neurotech’s patented core technology platform, Encapsulated Cell Technology (ECT), is a genetically engineered implant that enables the continuous delivery of protein drugs directly into the vitreous of the eye. The company has demonstrated that a single living ECT implant can treat a diseased retina for two years or more, thereby eliminating the need for monthly injections, the conventional approach to treating retinal disease.

Jim Mazzo’s 35-year career in the health care industry includes seven years as chairman, president and CEO of Advanced Medical Optics (AMO), which was sold to Abbott Labs in 2009 for $2.8 billion. He was previously with Allergan for over 20 years in a variety of expanding roles, working and living in the U.S., England, Italy and Canada. He led the spinoff of AMO from Allergan in 2002, expanding the business into a $1 billion industry-leading, publicly-traded corporation. Most recently, he has served as senior vice president, Abbott Laboratories and president, Abbott Medical Products.

Mondottica International Ltd. Names Tulba New Managing Director

 Steve Tulba

NOTTINGHAM, U.K. – Mondottica International Ltd. has announced the appointment of Steve Tulba as the group’s new managing director for Mondottica Limited, effective immediately.

Reporting to Michael Jardine, Mondottica International’s chairman, Tulba will assume overall management responsibility for the EMEA region and the Americas, the company said. Tulba’s new role takes over many of the responsibilities held by Mondottica’s former CEO, Bernhard Nuesser, who left the group in May for a position with Essilor SA.

Tulba is an industry veteran, having served in several key positions with Inspecs over the last decade. He was most recently based in Florida as president of Inspecs USA. He will be based at Mondottica’s European headquarters in Nottingham.

Haag-Streit Appoints Rom Business Development Manager

 Mike Rom

Mason, Ohio—Haag-Streit USA has appointed Mike Rom to the newly created position of business development manager, East. Rom will be working with distributors, teaching institutions, clinics and customers to build relationships and promote Haag-Streit and Reliance Medical Products. Rom has been with the company for 18 years. “The business development manager position is especially important as we continue to evolve and provide the best possible products and services to our customers,” said Ernest Cavin, president of Haag-Streit USA.

Headquartered in Bern, Switzerland, with its U.S. headquarters in Mason, Ohio, Haag-Streit manufactures optical instruments for ophthalmologists and optometrists. ■